Hollie Colucci
Family · West Warwick, RINPI 1205308913
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,026 of the $10,867 with a category attached, or 83.1%. It is spread thinly across 33 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $5,339 and has fallen 91.4% since, to $459 in 2025. Among family clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 278 payments — averaging $39.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$2K
- AbbVie$2K
- AstraZeneca$1K
- Johnson & Johnson$946
- Abbott$667
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$627
- plus $3K from 27 others
What the payments were for
- Travel & lodging$1,84117%
- Food & beverage$9,02683%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 3 | $2,157 |
| AbbVie | 88 | $1,585 |
| AstraZeneca | 33 | $1,481 |
| Johnson & Johnson | 22 | $946 |
| Abbott | 11 | $667 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $627 |
| Novo Nordisk | 14 | $452 |
| Lilly USA, LLC | 16 | $427 |
| Amgen | 8 | $340 |
| Vanda Pharmaceuticals Inc. | 10 | $305 |
| Mylan Specialty L.p. | 9 | $280 |
| Boehringer Ingelheim | 4 | $271 |
| Otsuka America Pharmaceutical, Inc. | 2 | $216 |
| Paratek Pharmaceuticals, Inc. | 5 | $168 |
| GSK | 7 | $143 |
| Pfizer | 5 | $103 |
| Sumitomo Pharma America, Inc. | 4 | $102 |
| Exact Sciences | 4 | $96 |
| Corium, LLC | 1 | $90 |
| Lundbeck LLC | 4 | $68 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Merck | 2 | $41 |
| Lucid Diagnostics Inc. | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 1 | $33 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Optinose US, Inc. | 1 | $25 |
| Halozyme Inc | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Novartis | 1 | $22 |
| Bayer | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,867 in reported general payments places this provider in the 95th percentile of 457 family providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 84 | $81,414 |
| VraylarCariprazine Hcl | 32 | $62,273 |
| EliquisApixaban | 66 | $50,535 |
| TrulicityDulaglutide | 42 | $49,489 |
| Nurtec OdtRimegepant Sulfate | 20 | $29,269 |
| FarxigaDapagliflozin Propanediol | 40 | $28,967 |
| CaplytaLumateperone Tosylate | 16 | $26,617 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $24,384 |
| OzempicSemaglutide | 20 | $22,463 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $22,391 |
| WegovySemaglutide | 17 | $21,442 |
| UbrelvyUbrogepant | 14 | $18,549 |
| MounjaroTirzepatide | 16 | $16,176 |
| RybelsusSemaglutide | 16 | $14,323 |
| XareltoRivaroxaban | 12 | $10,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Ubrelvy, Linzess | $1,585 | $90,43457 claims |
| Boehringer IngelheimJardiance | $271 | $81,41484 claims |
| PfizerEliquis, Nurtec Odt | $103 | $79,80486 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $427 | $65,66558 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $452 | $58,22853 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,481 | $54,60879 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $143 | $30,72444 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $627 | $26,61716 claims |
| Johnson & JohnsonXarelto | $946 | $10,58012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 family providers in Rhode Island.
Other family in West Warwick
- Michelle Blade MelloWest Warwick$12K
- Carol RobinsonWarwick$82K
- Mark ClarkeSmithfield$37K
- Olga FedorenkoCoventry$24K
- Alicia VatterWarwick$15K
- Kaleigh RapozaJohnston$14K
- David RamosRiverside$14K
- Sharon BensonNorth Smithfield$12K
- Shrenik VyasLincoln$11K
- Ashley LieseSmithfield$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.